EXECUTIVE SUMMARY

• Medartis Launches TITAN Nail System for Intramedullary Hand Fracture Fixation in the US: Medartis announced the official commercial US rollout of its TITAN Nail System, introducing an intramedullary alternative to traditional plate-and-screw constructs for phalangeal and metacarpal fractures.
• CMS Finalizes Higher Reimbursement for CERAMENT® G in FY2027 IPPS Final Rule: BONESUPPORT announced that CMS confirmed the Diagnosis-Related Groups (DRG) reassignment for CERAMENT® G, placing qualifying complex orthopaedic infection cases into the highest reimbursing DRGs.
• Maxx Orthopedics Expands Revision Knee Platform with PCK® Metaphyseal Cones: Maxx Orthopedics launched porous titanium PCK® Metaphyseal Cones to address severe proximal tibial bone loss in revision total knee arthroplasty.

DAILY ANNOUNCEMENTS BY CATEGORY

Trauma & Extremities

Medartis — Commercial Launch of TITAN Nail System for Hand Fractures in the United States

• Summary: Medartis Inc. announced the official commercial launch of the TITAN Nail System in the US market, expanding its upper extremity trauma portfolio. The system provides an intramedullary osteosynthesis solution specifically designed for extra-articular fractures of the phalanges and metacarpals. The first clinical procedure was performed by Dr. Kelly Babineaux at University Medical Center New Orleans. By stabilizing fractures from within the intramedullary canal rather than via dorsal or lateral plating, the system reduces soft-tissue dissection, extensor tendon irritation, and operating time.
• Key Details:
• Device/System Name: TITAN Nail System
• Status: Commercial Launch / FDA 510(k) Cleared
• Clinical Significance: Minimizes periosteal stripping and extensor tendon adhesions in hand trauma, facilitating earlier active mobilization and functional recovery.
• Original Source: Medartis Launch Press Release

Joint Reconstruction (Hip, Knee, Shoulder)

Maxx Orthopedics — Launches PCK® Metaphyseal Cones for Complex Revision Total Knee Arthroplasty

• Summary: Maxx Orthopedics announced the commercial U.S. launch of its PCK® Metaphyseal Cones, porous titanium devices engineered for structural reconstruction of severe metaphyseal bone defects (AORI Type II and III) during revision total knee replacement. The cones integrate seamlessly with both the Freedom® PCK® Revision Knee System and the Freedom® Titan PCK® Revision Knee System, providing rigid zonal fixation and biomechanical load sharing.
• Key Details:
• Device/System Name: PCK® Metaphyseal Cones (Freedom® PCK® Revision Knee System)
• Status: Commercial Launch / FDA 510(k) Cleared
• Clinical Significance: Provides robust structural metaphyseal support and biological fixation in complex revision TKA cases presenting significant bone loss.
• Original Source: Maxx Orthopedics Press Release on PRWeb

Spine & Orthobiologics

BONESUPPORT — CMS Finalizes Higher Reimbursement for CERAMENT® G in FY2027 IPPS Final Rule

• Summary: BONESUPPORT announced that the Centers for Medicare & Medicaid Services (CMS) confirmed the Diagnosis-Related Groups (DRG) reassignment for CERAMENT® G in the final Medicare Inpatient Prospective Payment System (IPPS) rule for fiscal year 2027 (effective October 1, 2026). Qualifying cases utilizing the gentamicin-eluting bone void filler for complex orthopaedic infections—including periprosthetic joint infection (PJI), fracture-related infections (FRI), and diabetic foot osteomyelitis—will be assigned to the highest reimbursing DRGs within their respective clinical categories. CMS also established a new dedicated procedure code for vancomycin-eluting bone void fillers (CERAMENT® V).
• Key Details:
• Device/System Name: CERAMENT® G (Gentamicin-Eluting Bone Void Filler)
• Status: Regulatory Reimbursement Milestone / CMS IPPS Final Rule
• Clinical Significance: Eliminates financial barriers for inpatient hospital adoption, improving access to single-stage local antibiotic eluting bone graft treatment in complex musculoskeletal infections.
• Original Source: BONESUPPORT Official Press Release

Isto Biologics — Completes $60M Acquisition of NovaBone to Expand Synthetic Bone Graft Platform

• Summary: Isto Biologics completed the acquisition of Florida-based NovaBone Products from Halma plc for $60 million. The transaction significantly enhances Isto's orthobiologics portfolio with bioactive glass synthetic bone graft substitutes, expanding its commercial reach across spine fusion, orthopaedic trauma, and foot/ankle surgery.
• Key Details:
• Device/System Name: NovaBone Bioactive Synthetic Bone Graft Portfolio
• Status: Strategic M&A Completed
• Clinical Significance: Broadens surgeon access to osteostimulative bioactive glass matrices that promote cellular attachment and rapid bone regeneration in skeletal voids.
• Original Source: Isto Biologics Press Release

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)